PP_1170x120_10-25-21

Janssen Scientific Affairs

FDA OKs new indications for Janssen’s Simponi Aria

FDA OKs new indications for Janssen’s Simponi Aria

HORSHAM, Pa. — Janssen Biotech Inc. has gained Food and Drug Administration approval for Simponi Aria (golimumab) to treat adults with active psoriatic arthritis or active ankylosing spondylitis. Janssen said Simponi Aria is the only fully-human anti-tumor necrosis factor-alpha therapy administered via a 30-minute infusion. The latest indication follows Simponi Aria’s first FDA approval in